ITI MF

CATEGORY OF SCHEME	Sectoral/Thematic
INVESTMENT OBJECTIVE	The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. However, there can be no assurance that the investment objective of the scheme would be achieved.
Inception Date (Date of Allotment):	08-Nov-21
Benchmark:	Nifty Healthcare TRI
Minimum Application Amount:	Rs.5,000/- and in multiples of Rs. 1/- thereafter
Load Structure:	Entry Load: Nil Exit Load: 1% if redeemed or switched out on or before completion of 12 months from the date of allotment of units · Nil, if redeemed or switched out after completion of 12 months from the date of allotment of units.
Total Expense Ratio (TER):	Including Additional Expenses and Goods and Service Tax on Management Fees Regular Plan: 2.35% Direct Plan: 0.47%
Fund Manager	Mr. Rohan Korde (Since 08-Nov-21) Total Experience: 19 years Mr. Dhimant Shah (Since 01 December 2022) Total Experience : 26 years

AUM (in Rs. Cr):	208.21
AAUM (in Rs. Cr):	203.26
% of top 5 holdings:	38.57%
% of top 10 holdings:	54.96%
No. of scrips:	39

Standard Deviation^:	NA
Beta^:	NA
*Sharpe Ratio^:**	NA
Average P/B	8.32
Average P/E	47.61
Portfolio Turnover Ratio	0.62
^Scheme has not completed 3 years hence NA * Risk free rate: 6.61 (Source: FIMMDA MIBOR)

	Regular Plan (in Rs.)	Direct Plan (in Rs.)
Growth:	16.9941	18.0767
IDCW:	16.9941	18.0767

Name of the Instrument	% to NAV	% to NAV Derivatives
Equity & Equity Related Total	98.20
Chemicals	1.98
Sumitomo Chemical India Limited	1.03
Archean Chemical Industries Limited	0.96
Financial Services	1.20
HDFC Life Insurance Company Limited	1.20
Healthcare	95.02
Sun Pharmaceutical Industries Limited	15.60
Lupin Limited	6.72
Suven Pharmaceuticals Limited	6.06
Apollo Hospitals Enterprise Limited	5.42
Divi's Laboratories Limited	4.76
Aurobindo Pharma Limited	3.94
Dr. Reddy's Laboratories Limited	3.38
Zydus Lifesciences Limited	3.11
IPCA Laboratories Limited	3.05
Laurus Labs Limited	2.90
Syngene International Limited	2.59
Piramal Pharma Limited	2.38
Max Healthcare Institute Limited	2.15
Aster DM Healthcare Limited	2.09
Orchid Pharma Limited	1.97
Torrent Pharmaceuticals Limited	1.95
Strides Pharma Science Limited	1.91
Alkem Laboratories Limited	1.81
Healthcare Global Enterprises Limited	1.72
FDC Limited	1.69
Shilpa Medicare Limited	1.65
Mankind Pharma Limited	1.54
Caplin Point Laboratories Limited	1.44
Vijaya Diagnostic Centre Limited	1.44
Fortis Healthcare Limited	1.35
Ajanta Pharma Limited	1.34
Rainbow Childrens Medicare Limited	1.25
Gland Pharma Limited	1.21
Supriya Lifescience Limited	1.20
GlaxoSmithKline Pharmaceuticals Limited	1.20
Cipla Limited	1.15
Emcure Pharmaceuticals Limited	1.11
Biocon Limited	1.07
Neuland Laboratories Limited	1.05
Alembic Pharmaceuticals Limited	1.05
Wockhardt Limited	0.76
Short Term Debt & Net Current Assets	1.80

Top Ten Holdings

Period	Fund Returns (%)	Benchmark Returns (%)	Additional Benchmark Returns (%)	Benchmark (Rs)	Fund (Rs)	Additional Benchmark Returns (Rs)
Regular - Growth
Last 1 Year	58.93%	56.61%	28.30%	15,914	15,680	12,839
Since Inception	19.47%	19.64%	11.63%	16,994	17,067	13,881
Direct - Growth
Last 1 Year	61.96%	56.61%	28.30%	16,218	15,680	12,839
Since Inception	21.97%	19.64%	11.63%	18,077	17,067	13,881

Past performance may or may not be sustained in future and is not a guarantee of any future returns, and should not be used as a basis of comparison with other investments. The performance data for 3 years period has not been provided, since scheme is in existence for less than 3 years. In case, the start / end date of the concerned period is a non-business date (NBD), the NAV of the previous date is considered for computation of returns. Different Plans i.e. Regular Plan and Direct Plan under the scheme have different expense structure. Benchmark: Nifty Healthcare TRI Additional Benchmark: Nifty 50 TRI. Fund Managers: Mr. Rohan Korde (Managing since 08-Nov-21) and Mr. Dhimant Shah (Managing since 01-December-22). Inception date of the scheme is (08-Nov-2021). Face Value per unit: Rs. 10.ITI Pharma & Healthcare Fund NAV as on October 31, 2024: Rs. 16.9941 (Regular Growth Option), Rs. 18.0767 (Direct Growth Option)

Period	Amount Invested	Fund Value ()	Fund Returns (%)	Benchmark Value ()	Benchmark Returns (%)	Additional Benchmark Value ()	Additional Benchmark Returns (%)
Regular - Growth
Last 1 Year	1,20,000	1,50,687	50.46%	1,46,278	42.85%	1,29,344	14.72%
Since Inception	3,60,000	5,76,416	33.08%	5,68,720	32.06%	4,64,216	17.22%
Direct - Growth
Last 1 Year	1,20,000	1,52,325	53.31%	1,46,278	42.85%	1,29,344	14.72%
Since Inception	3,60,000	5,95,936	35.62%	5,68,720	32.06%	4,64,216	17.22%

Past performance may or may not be sustained in future and is not a guarantee of any future returns, and should not be used as a basis of comparison with other investments. Different Plans i.e. Regular Plan and Direct Plan under the scheme have different expense structure. Benchmark: Nifty Healthcare TRI Additional Benchmark: Nifty 50 TRI. For SIP returns, monthly investment of Rs.10,000 invested on the 1st business day of every month has been considered. CAGR Returns (%) are computed after accounting for the cash flow by using the XIRR method (investment internal rate of return).